BioCentury
ARTICLE | Clinical News

AIR DNase: Completed Ph II enrollment

December 30, 2016 1:45 AM UTC

Protalix completed enrollment of 15 patients switching over from Pulmozyme dornase alfa in an open-label, Israeli Phase II trial evaluating 2.5 mg inhaled AIR DNase once daily for 28 days....

BCIQ Company Profiles

Protalix BioTherapeutics Inc.